Analyst Consensus ?
ConsensusHold27 ratings
Bullish725.9%
Neutral1659.3%
Bearish414.8%
FN2 Earnings Intelligence
Moderna, Inc. complete analyst coverage
Moderna, Inc. (MRNA) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$57.92Current
$15Low
$108.6Average
$350High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 21, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 8, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Jul 7, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 7, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jun 26, 2026 |
| UBS | Neutral | Neutral | Maintain | May 4, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | May 4, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Apr 2, 2026 |
| Leerink Partners | Underperform | Underperform | Maintain | Nov 21, 2025 |
| JP Morgan | Underweight | Underweight | Maintain | Oct 23, 2025 |
| Citigroup | Neutral | Neutral | Maintain | Oct 23, 2025 |
| Needham | Hold | Hold | Maintain | Oct 20, 2025 |
| Argus Research | Hold | Buy | Downgrade | Dec 18, 2024 |
| HSBC | Buy | Hold | Upgrade | Nov 18, 2024 |
| Deutsche Bank | Hold | Sell | Upgrade | Aug 6, 2024 |
| Oppenheimer | Outperform | Outperform | Maintain | Jun 12, 2024 |
| Canaccord Genuity | Hold | Hold | Maintain | May 3, 2024 |
| Jefferies | Buy | Buy | Maintain | Apr 9, 2024 |
| TD Cowen | Market Perform | Outperform | Downgrade | Aug 4, 2023 |
| Guggenheim | Neutral | Neutral | Maintain | Apr 26, 2023 |
| SVB Leerink | Underperform | Market Perform | Downgrade | Feb 24, 2023 |
| Cowen & Co. | Market Perform | Market Perform | Maintain | Jan 25, 2023 |
| Chardan Capital | Neutral | Neutral | Maintain | Jan 18, 2023 |
| Wolfe Research | Outperform | Outperform | Maintain | Nov 9, 2021 |
| Brookline Capital | Buy | Buy | Maintain | Feb 26, 2021 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 1, 2021 |
| BMO Capital | Outperform | Outperform | Maintain | Nov 25, 2020 |
Named analyst price targets
Upside is calculated against the persisted current price $57.92. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Goldman Sachs | Analyst unavailable | $67 | $59.49 | +15.7% | Jul 21, 2026 |
| Wolfe Research | Alexandria Hammond | $25 | $61.82 | -56.8% | Jul 20, 2026 |
| Morgan Stanley | Analyst unavailable | $39 | $79.77 | -32.7% | Jul 8, 2026 |
| RBC Capital | Analyst unavailable | $45 | $81.8 | -22.3% | Jul 7, 2026 |
| Piper Sandler | Analyst unavailable | $77 | $67.66 | +32.9% | Jun 26, 2026 |
| UBS | Analyst unavailable | $45 | $47.46 | -22.3% | May 4, 2026 |
| RBC Capital | Luca Issi | $38 | $46.87 | -34.4% | May 4, 2026 |
| Goldman Sachs | Analyst unavailable | $49 | $45.37 | -15.4% | May 1, 2026 |
| Morgan Stanley | Analyst unavailable | $33 | $44.18 | -43.0% | May 1, 2026 |
| Jefferies | Andrew Tsai | $37 | $49.83 | -36.1% | Mar 3, 2026 |
| RBC Capital | Luca Issi | $30 | $42.54 | -48.2% | Feb 17, 2026 |
| Evercore ISI | Cory Kasimov | $35 | $43.19 | -39.6% | Feb 17, 2026 |
| Bernstein | Analyst unavailable | $45 | $42.23 | -22.3% | Feb 17, 2026 |
| UBS | Analyst unavailable | $36 | $42.23 | -37.8% | Feb 16, 2026 |
| Morgan Stanley | Analyst unavailable | $30 | $42.23 | -48.2% | Feb 16, 2026 |
| UBS | Analyst unavailable | $34 | $35.66 | -41.3% | Jan 6, 2026 |
| Morgan Stanley | Analyst unavailable | $28 | $29.9 | -51.7% | Dec 12, 2025 |
| Jefferies | Analyst unavailable | $30 | $29.62 | -48.2% | Dec 12, 2025 |
| RBC Capital | Luca Issi | $25 | $23.1 | -56.8% | Nov 21, 2025 |
| UBS | Analyst unavailable | $18 | $22.36 | -68.9% | Nov 21, 2025 |
| Piper Sandler | Analyst unavailable | $63 | $22.36 | +8.8% | Nov 21, 2025 |
| Wolfe Research | Analyst unavailable | $17 | $22.36 | -70.6% | Nov 20, 2025 |
| Berenberg Bank | Analyst unavailable | $28 | $24.77 | -51.7% | Nov 17, 2025 |
| UBS | Analyst unavailable | $40 | $26.85 | -30.9% | Oct 23, 2025 |
| Leerink Partners | Analyst unavailable | $15 | $27.12 | -74.1% | Aug 22, 2025 |
| Evercore ISI | Cory Kasimov | $32 | $29.56 | -44.8% | Aug 1, 2025 |
| Evercore ISI | Cory Kaimov | $50 | $31.92 | -13.7% | Feb 14, 2025 |
| Piper Sandler | Edward Tenthoff | $69 | $37.27 | +19.1% | Nov 18, 2024 |
| HSBC | Yifeng Liu | $58 | $84.93 | +0.1% | Nov 18, 2024 |
| Bernstein | Courtney Breen | $55 | $57.46 | -5.0% | Oct 17, 2024 |
| Jefferies | Michael Yee | $55 | $57.73 | -5.0% | Oct 14, 2024 |
| Piper Sandler | Edward Tenthoff | $115 | $69.68 | +98.5% | Sep 13, 2024 |
| RBC Capital | Luca Issi | $75 | $69.68 | +29.5% | Sep 13, 2024 |
| Loop Capital Markets | Leah Rush Cann | $238 | $69.68 | +310.9% | Sep 13, 2024 |
| Jefferies | Michael Yee | $65 | $69.68 | +12.2% | Sep 12, 2024 |
| Evercore ISI | Cory Kasimov | $105 | $67.68 | +81.3% | Sep 12, 2024 |
| Morgan Stanley | Matthew Harrison | $94 | $67.51 | +62.3% | Sep 12, 2024 |
| Jefferies | Michael Yee | $120 | $67.52 | +107.2% | Sep 12, 2024 |
| Robert W. Baird | Peter Arment | $220 | $78.52 | +279.8% | Aug 28, 2024 |
| HSBC | Yifeng Liu | $82 | $78.98 | +41.6% | Aug 28, 2024 |
| Deutsche Bank | Emmanuel Papadakis | $80 | $82.3 | +38.1% | Aug 6, 2024 |
| RBC Capital | Luca Issi | $90 | $86.58 | +55.4% | Aug 5, 2024 |
| Piper Sandler | Edward Tenthoff | $157 | $90.03 | +171.1% | Aug 2, 2024 |
| Oppenheimer | Hartaj Singh | $179 | $148.39 | +209.0% | Jun 12, 2024 |
| Loop Capital Markets | Leah Rush Cann | $310 | $147.47 | +435.2% | Jun 10, 2024 |
| Jefferies | Michael Yee | $180 | $152.03 | +210.8% | Jun 7, 2024 |
| RBC Capital | Luca Issi | $160 | $141.83 | +176.2% | May 31, 2024 |
| Evercore ISI | Cory Kasimov | $120 | $125.67 | +107.2% | May 13, 2024 |
| Deutsche Bank | Emmanuel Papadakis | $85 | $124.06 | +46.8% | May 9, 2024 |
| UBS | Eliana Merle | $151 | $122.13 | +160.7% | May 7, 2024 |
| Jefferies | Michael Yee | $155 | $123.02 | +167.6% | May 3, 2024 |
| Canaccord Genuity | Bill Maughan | $106 | $125.59 | +83.0% | May 3, 2024 |
| Oppenheimer | Hartaj Singh | $163 | $125.59 | +181.4% | May 3, 2024 |
| RBC Capital | Luca Issi | $135 | $125.59 | +133.1% | May 3, 2024 |
| Morgan Stanley | Matthew Harrison | $95 | $125 | +64.0% | May 2, 2024 |
| Morgan Stanley | Matthew Harrison | $89 | $108.85 | +53.7% | Apr 24, 2024 |
| Jefferies | Michael Yee | $125 | $110.59 | +115.8% | Mar 28, 2024 |
| UBS | Eliana Merle | $143 | $107.41 | +146.9% | Mar 27, 2024 |
| Morgan Stanley | Matthew Harrison | $123 | $87.59 | +112.4% | Feb 22, 2024 |
| Oppenheimer | Hartaj Singh | $142 | $113.15 | +145.2% | Jan 2, 2024 |
| UBS | Eliana Merle | $191 | $121.14 | +229.8% | Jun 26, 2023 |
| Piper Sandler | Analyst unavailable | $217 | $189.89 | +274.7% | Dec 20, 2022 |
| Jefferies | Analyst unavailable | $275 | $193.29 | +374.8% | Dec 19, 2022 |
| Morgan Stanley | Analyst unavailable | $209 | $191.78 | +260.8% | Dec 16, 2022 |
| Chardan Capital | Analyst unavailable | $191 | $212.4 | +229.8% | Dec 14, 2022 |
| Leerink Partners | Analyst unavailable | $102 | $197.54 | +76.1% | Dec 13, 2022 |
| Argus Research | Jasper Hellweg Hellweg | $150 | $123.64 | +159.0% | Sep 24, 2022 |
| Piper Sandler | Edward Tenthoff | $214 | $142.28 | +269.5% | May 17, 2022 |
| Morgan Stanley | Matthew Harrison | $199 | $155.05 | +243.6% | May 4, 2022 |
| Piper Sandler | Edward Tenthoff | $348 | $176.59 | +500.8% | Apr 1, 2022 |
| Morgan Stanley | Matthew Harrison | $205 | $173.08 | +253.9% | Mar 28, 2022 |
| Deutsche Bank | Emmanuel Papadakis | $155 | $129.28 | +167.6% | Mar 8, 2022 |
| Jefferies | Michael Yee | $170 | $151.33 | +193.5% | Feb 27, 2022 |
| Barclays | Gena Wang | $210 | $156.23 | +262.6% | Feb 24, 2022 |
| Cowen & Co. | Tyler Van Buren | $200 | $172.74 | +245.3% | Feb 1, 2022 |
| Deutsche Bank | Emmanuel Papadakis | $175 | $154.96 | +202.1% | Jan 26, 2022 |
| UBS | Eliana Merle | $221 | $160.07 | +281.6% | Jan 21, 2022 |
| Argus Research | Jasper Hellweg | $350 | $216.06 | +504.3% | Jan 6, 2022 |
| Wolfe Research | Andrew Galler | $304 | $244.68 | +424.9% | Nov 8, 2021 |
| J.P. Morgan | Cory Kasimov | $165 | $284.02 | +184.9% | Nov 4, 2021 |
| Wells Fargo | Nick Abbott | $145 | $234.46 | +150.3% | Jun 29, 2021 |
| Chardan Capital | Geulah Livshits | $188 | $185.01 | +224.6% | May 28, 2021 |
Track every rating change on MRNA the moment it posts. Free to start.
Start free